NASDAQ: HSCSHeartsciences Inc Stock
$3.20-0.10 (-3.03%)
Updated Apr 21, 2025
HSCS Price
$3.20
Fair Value Price
N/A
Market Cap
$3.46M
52 Week Low
$2.36
52 Week High
$13.50
P/E
-0.43x
P/B
1.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.19
Operating Cash Flow
-$7M
Beta
0.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HSCS Overview
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HSCS's potential to beat the market
- HSCS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
B
HSCS
RankedUnranked of 103
RankedUnranked of 103
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.50 | A | |
| $22.62 | A | |
| $13.45 | A |
Be the first to know about important HSCS news, forecast changes, insider trades & much more!
HSCS News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HSCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSCS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HSCS is good value based on its book value relative to its share price (1.94x), compared to the US Medical Devices industry average (3.74x)
P/B vs Industry Valuation
HSCS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HSCS due diligence checks available for Premium users.
Valuation
HSCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
40.34x
Market
27.14x
HSCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.94x
Industry
3.74x
HSCS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HSCS's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
HSCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.7M
Liabilities
$3.9M
Debt to equity
2.19
HSCS's short-term assets ($3.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSCS's short-term assets ($3.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$15.7k
Financing
$180.2k
HSCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSCS vs Medical Device Stocks
Heartsciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.